Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focusing on neuroplastogens for neuropsychiatric disorders, will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. CEO Joseph Tucker, Ph.D., will deliver a virtual presentation on September 9 at 7:00 AM ET, discussing:
- Development of novel neuroplastogenic small-molecule therapeutics for depression, anxiety, and addiction disorders
- Recent data on lead candidate EB-003, confirming oral bioavailability and significant brain exposure
- Enveric's strategy to maximize value from assets developed using their AI-backed drug discovery engine
Investors can register for the conference at https://hcwevents.com/annualconference/
Enveric Biosciences (NASDAQ: ENVB), un'azienda biotecnologica che si concentra sui neuroplastogeni per i disturbi neuropsichiatrici, prenderà parte alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright che si svolgerà dal 9 all'11 settembre 2024. Il CEO Joseph Tucker, Ph.D., presenterà una presentazione virtuale il 9 settembre alle 7:00 AM ET, durante la quale discuterà:
- Sviluppo di nuovi terapeutici a piccole molecole neuroplastogeniche per depressione, ansia e disturbi da dipendenza
- Dati recenti sul candidato principale EB-003, che confermano la biodisponibilità orale e un'esposizione cerebrale significativa
- La strategia di Enveric per massimizzare il valore delle risorse sviluppate utilizzando il loro motore di scoperta di farmaci supportato da intelligenza artificiale
Gli investitori possono registrarsi per la conferenza su https://hcwevents.com/annualconference/
Enveric Biosciences (NASDAQ: ENVB), una empresa de biotecnología centrada en neuroplastógenos para trastornos neuropsiquiátricos, participará en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright que se llevará a cabo del 9 al 11 de septiembre de 2024. El CEO Joseph Tucker, Ph.D., realizará una presentación virtual el 9 de septiembre a las 7:00 AM ET, en la que hablará sobre:
- Desarrollo de nuevos terapéuticos de pequeñas moléculas neuroplastogénicas para la depresión, la ansiedad y los trastornos de adicción
- Datos recientes sobre el candidato principal EB-003, confirmando la biodisponibilidad oral y una exposición cerebral significativa
- Estrategia de Enveric para maximizar el valor de los activos desarrollados utilizando su motor de descubrimiento de fármacos respaldado por IA
Los inversionistas pueden registrarse para la conferencia en https://hcwevents.com/annualconference/
엔베릭 바이오사이언스 (NASDAQ: ENVB), 신경정신 장애를 위한 신경플라스모겐에 주력하는 생명공학 회사는 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 2024년 9월 9일부터 11일까지 참석할 예정입니다. CEO 조셉 터커, Ph.D.는 9월 9일 오전 7:00 ET에 가상의 발표를 진행하며 다음 주제를 다룰 예정입니다:
- 우울증, 불안 및 중독 장애를 위한 새로운 신경플라스모겐 소분자 치료제 개발
- 주요 후보 EB-003에 대한 최근 데이터, 경구 생체이용률 및 중추신경계에서의 유의미한 노출 확인
- 자사의 인공지능 기반 약물 발견 엔진을 사용하여 개발된 자산의 가치를 극대화하기 위한 엔베릭의 전략
투자자들은 https://hcwevents.com/annualconference/에서 회의에 등록할 수 있습니다.
Enveric Biosciences (NASDAQ: ENVB), une entreprise biotechnologique axée sur les neuroplastogènes pour les troubles neuropsychiatriques, participera à la 26ème Conférence Annuelle Mondiale sur l'Investissement H.C. Wainwright qui se déroulera du 9 au 11 septembre 2024. Le PDG Joseph Tucker, Ph.D., présentera une présentation virtuelle le 9 septembre à 7h00 ET, au cours de laquelle il abordera :
- Le développement de nouveaux thérapeutiques à petites molécules neuroplastogéniques pour la dépression, l'anxiété et les troubles de la dépendance
- Des données récentes sur le candidat principal EB-003, confirmant la biodisponibilité orale et une exposition cérébrale significative
- La stratégie d'Enveric pour maximiser la valeur des actifs développés via leur moteur de découverte de médicaments soutenu par l'IA
Les investisseurs peuvent s'inscrire à la conférence sur https://hcwevents.com/annualconference/
Enveric Biosciences (NASDAQ: ENVB), ein Biotechnologieunternehmen, das sich auf Neuroplastogenese bei neuropsychiatrischen Störungen konzentriert, wird an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright vom 9. bis 11. September 2024 teilnehmen. CEO Joseph Tucker, Ph.D., wird am 9. September um 7:00 Uhr ET eine virtuelle Präsentation halten, in der er über Folgendes sprechen wird:
- Entwicklung neuartiger neuroplastogener Kleinstmoleküle zur Behandlung von Depression, Angst und Suchtstörungen
- Aktuelle Daten zum Hauptkandidaten EB-003, die die orale Bioverfügbarkeit und signifikante Hirnexposition bestätigen
- Enverics Strategie zur Maximierung des Wertes aus Vermögenswerten, die mit ihrer KI-gestützten Arzneimittelentdeckungsmaschine entwickelt wurden
Investoren können sich unter https://hcwevents.com/annualconference/ für die Konferenz registrieren.
- None.
- None.
During the presentation, Dr. Tucker will discuss the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, including its lead candidate EB-003, for which the company recently announced data confirming oral bioavailability and significant brain exposure. Additionally, Dr. Tucker will discuss Enveric’s strategy to maximize the value of the assets developed using the Company’s AI-backed drug discovery engine.
Presentation Details:
Event: |
H.C. Wainwright 26th Annual Global Investment Conference |
Date: |
September 9-11, 2024 |
Virtual Presentation: |
7:00 AM, ET, September 9, 2024 |
Registration: |
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary™, Enveric has created a robust intellectual property portfolio of new chemical entities for specific mental health indications. Enveric’s lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, a next generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders. Enveric is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “explores,” “schedules,” “seeks,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: negotiate and finalize definitive agreements based on the any of its out-licensing term sheets and perform pursuant to the terms thereof; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904463238/en/
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
Source: Enveric Biosciences
FAQ
When is Enveric Biosciences (ENVB) presenting at the H.C. Wainwright Global Investment Conference?
What will Enveric Biosciences (ENVB) discuss in their presentation at the H.C. Wainwright conference?
What recent data did Enveric Biosciences (ENVB) announce about their lead candidate EB-003?
How can investors register for the H.C. Wainwright conference where Enveric Biosciences (ENVB) is presenting?
